Hyderabad: In the movement that will soon increase the production capacity of Covid-19 Covaxin developed by the original, Immunologicals Ltd (IIL) on Friday handed the first batch of covax medicine to Bharat Biotech.
While to start with IIL will supply drug substances around 3 to 4 million per month, from December, this will increase up to 10 million doses per month, Iil Director of Implementing Dr.
K Anand Kumar said on the opportunity to handle first of the covaxin drug Bharat Biotech Chairman and Managing Director Dr.
Krishna Ella with a simple attack on the ceremony.
IIL and Bharat Biotech have signed an agreement for the same thing on April 2021 after that IIL transmits the BSL-2 facility + manufacturing anti-rabies vaccine in Karakapatla in Genome Valley.
IIL, which signed four agreements with Bharat Biotech, able to reuse its manufacturing facilities in Hyderabad, get raw materials and consumables and key equipment for processes, technology transfers, trials on the R & D scale, training and training in time and production training Started in July 2021.
“The batch produced in IIL manufacturing facilities has been tested in BBIL and IIL and meets quality specifications for medicine.
The results are more than expected,” said Dr.
Anand Kumar.
“This is an Indian team at work.
It is not possible without coming along with several shareholders to achieve a common goal.
Our capable and competent team works tirelessly all the time to ensure that the schedule that is committed and the quality of the product is fulfilled.” “This is a moment which boasts for IIL to play an important role in supporting the interests of our nation during an unprecedented time.
This will not be possible without constant support provided by Niti-Aayog, BIRAC, DBT, Mission Covid Surakha Tim, Central and County Narcotics Control Drugs , “he added.
Dr.
Renu Swarup, Secretary of DBT and Chair of BIRAC said, “Liberal License Agreement by CDSCO for Immunology India Ltd.
to produce covaxin drugs is a major milestone, achieved in a very short time span.
DBT-BIRAC support under the Mission Covid Surakha aims to meet Our Covid-19 Vaccine needs.
“IIL approved Hospital 60 Crore grants to improve production capabilities as part of the Surakha Covid mission.
In addition to producing covaxin drug substances, IIL also working on the Covid-19 vaccine itself which is currently undergoing an ongoing animal trial with the expected vaccine ready for human vaccination next year, said Dr.
Anand Kumar.
IIL started the supply of covaxin medicine to Bio Bio for 3-4 million doses per month
